



## FE DE ERRATAS – ERRATUM

En el artículo

### **Cardiovascular disease markers responses in male receiving improved-fat meat-products vary by initial LDL-cholesterol levels.**

**La respuesta de marcadores de enfermedad cardiovascular al consumo de cárnicos con composición grasa mejorada depende de los niveles iniciales de LDL-colesterol.**

Paloma Celada<sup>1</sup>, Francisco José Sánchez-Muniz<sup>1</sup>, Gonzalo Delgado-Pando<sup>2</sup>, Sara Bastida<sup>1</sup>, Manuel Espárrago-Rodilla<sup>3</sup>, Francisco Jiménez-Colmenero<sup>2</sup>, Begoña Olmedilla-Alonso<sup>2</sup>.

<sup>1</sup>Departamento de Nutrición y Bromatología I (Nutrición). Facultad de Farmacia. Universidad Complutense. Madrid. España.

<sup>2</sup>Instituto de Ciencia y Tecnología de los Alimentos y Nutrición (ICTAN), CSIC. 28040-Madrid. España.

<sup>3</sup>Servicio de Análisis. Hospital de Mérida. Badajoz. España.

Publicado en JONNPR 2016;1(6):229-236 DOI: 10.19230/jonnpr.2016.1.6.1088

Los autores han detectado los siguientes errores:

En la página 232 en la Tabla 2 en la fila 3 de datos en la columna Final NF debe llevar 1 asterisco (\*). La fila 4 Final n-3RF donde hay dos asteriscos (\*\*) solo debe haber 1 (\*). Final NF donde dice  $3.82 \pm 0.61$  debe decir  $4.06 \pm 0.79$ ; en la columna NF rate of change donde dice -0.1 (-11.6, 11.4) debe poner 8.6 (-5.9, 23.1) y en la columna p+ donde pone 0.24 debe poner 0.18.

En la página 229, en el abstract, en la tercera línea, en lugar de "sequentially" debe poner "crossover".

En la página 231, en Intervention study design, en la primera línea, en lugar de "sequentially" debe poner "crossover".

\* Autor para correspondencia.

Correo electrónico: [frasan@ucm.es](mailto:frasan@ucm.es) (Francisco José Sánchez-Muniz).

Recibido el 31 de marzo de 2017; aceptado el 10 de abril de 2017.



Tabla publicada con errores:

**Table 2.** Rate of change of cardiovascular disease markers to the three experimental pork products in subjects with initial low-normal/high LDL-cholesterol values

	Initial LDL-c <sup>1</sup>	Basal RF	Final RF	RF Rate of change	Basal n-3RF	Final n-3RF	n3RF Rate of change	Basal NF	Final NF	NF Rate of change	p+
Total cholesterol, mmol/L	1	5.76±0.73	5.69±0.67	-0.9 (-9.0, 7.2)	5.74±0.79	5.70±0.63	0.1 (-9.9, 10.0)	5.49±0.92	5.92±0.85*	8.5 (0.4, 16.7)	0.22
	2	6.05±0.28	6.13±0.27	1.3 (-1.9, 4.6)	5.84±0.46	6.23±0.58	7.1 (-0.6, 14.8)	6.21±0.74	6.01±0.51	-2.6 (-9.3, 4.0)	0.13
LDL-cholesterol, mmol/L	1	2.89±0.34	3.04±0.66	4.6 (-8.5, 17.7)	3.14±0.52	2.93±0.41	-4.2 (-20.2, 11.8)	2.94±0.41	3.3±0.82	11.7 (-6.1, 29.6)	0.31
	2	3.75±0.38	3.84±0.54	2.4 (-6.5, 11.3)	3.83±0.67	3.52±0.56**	-7.4 (-12.8, -2.1)	3.86±0.52	3.82±0.61	-0.1 (-11.6, 11.4)	0.24
HDL-cholesterol, mmol/L	1	1.14±0.24	1.21±0.26	6.6 (-0.9, 14.1)	1.27±0.22	1.27±0.25	-0.3 (-10.1, 9.5)	1.22±0.2	1.20±0.26	-2.1 (-11.5, 7.4)	0.18
	2	1.21±8.1	1.22±9.2	0.8 (-6.5, 8.1)	1.18±9.0	1.21±8.0	4.0 (-7.2, 15.1)	1.21±7.7	1.27±10.9	4.7 (-6.4, 15.7)	0.80
Triglycerides, mmol/L	1	1.59±1.1	1.37±0.35	10.2 (-24.8, 45.2)	1.22±0.52	1.46±0.59	-24.7 (-12.4, 61.7)	1.53±1.08	1.37±0.64	17.5 (-21.2, 56.3)	0.80
	2	1.39±0.67	1.26±0.62	-3.1 (-30.7, 24.5)	1.40±0.57	1.57±1.06	7.5 (-16.0, 31.0)	1.55±0.83	1.28±0.48	-3.1 (-31.0, 24.7)	0.66
Arylesterase, U/L	1	321±122	385±106	33.4 (-11.0, 77.7)	335±124	438±127**	37.6 (11.4, 63.7)	214±55.2	225±69.4	10.1 (-23.9, 44.2)	0.48
	2	266±62.2	348±108**	29.9 (14.6, 45.2) <sup>b</sup>	240±109	397±119***	81.8 (46.8, 116.8) <sup>a</sup>	196±38.2	179±59.0	-7.7 (-31.1, 15.6) <sup>c</sup>	0.001
oxLDL, U/L	1	53.7±12.2	49.6±7.9	-5.4 (-18.4, 7.6)	53.7±12.2	54.2±15.9	3.7 (-29.7, 37.1)	53.7±12.2	64.9±20.4	22.0 (-5.1, 49.1)	0.17
	2	59.7±7.2	61.9±7.3	4.0 (-3.0, 11.1) <sup>ab</sup>	59.7±7.2	59.8±11.3	0.3 (-9.9, 10.5) <sup>b</sup>	59.7±7.2	65.8±9.1	11.3 (-1.8, 24.5) <sup>a</sup>	0.049
CRP <sup>2</sup> , µg/mL	1	4.0±5.9	3.0±3.2	43.7 (-46.1, 133.5) <sup>a</sup>	3.9±3.4	2.1±2.5**	-61.0 (-92.6, -29.3) <sup>b</sup>	5.4±5.1	5.2±6.8	30.9 (-103, 164) <sup>ab</sup>	0.14
	2	1.8±2.2	1.5±1.0	92.4 (-68.8, 253.7)	1.8±1.4	2.4±3.1	183.8 (-131.5, 499)	1.7±0.8	2.4±2.1	39.8 (-14.4, 94.0)	0.46
TNFα, pg/mL	1	26.4±10.4	17.9±6.9*	-27.1 (-49.9, -4.3)	20.8±9.0	16.8±11.6	-21.2 (-50.5, 8.0)	26.4±17.1	15.3±13.2	-17.8 (76.6, 40.9)	0.87
	2	29.6±15.4	18.7±10.7	-24.5 (-55.1, 6.2)	16.1±12.2	17.9±5.2	140 (-93.3, 373)	21.6±12.7	24.4±15.5	39.2 (-45.0, 123.4)	0.19
apo A1, g/L	1	1.45±0.23	1.47±0.26	1.3 (-2.1, 4.6)	1.47±0.23	1.53±0.28	4.7 (-7.3, 16.6)	1.47±0.24	1.43±0.28	-2.9 (-8.0, 2.2)	0.33
	2	1.39±0.17	1.37±0.18	-1.3 (-5.6, 3.0)	1.36±0.2	1.35±0.17	-0.2 (-7.1, 6.7)	1.37±0.18	1.41±0.24	3.4 (-5.8, 12.7)	0.58
apo B, g/L	1	1.08±0.26	1.04±0.22	-2.8 (-10.3, 4.6)	1.05±0.24	1.00±0.23	-4.4 (-17.7, 8.9)	1.03±0.37	1.04±0.26	3.4 (-7.6, 14.4)	0.51
	2	1.15±0.12	1.15±0.12	0.2 (-4.2, 4.5)	1.10±0.14	1.17±0.14**	6.1 (1.3, 10.6)	1.15±0.11	1.13±0.13	-1.6 (-7.3, 4.2)	0.12
Lp(a), mg/L	1	78.5±95.9	84.7±102.8	7.9 (-15.4, 31.2)	78.1±92.5	74.3±93.5	-6.2 (-21.6, 9.2)	81.4±109.5	85.9±109.4	7.2 (-3.4, 17.8)	0.32
	2	112.1±111.5	98.1±92.4	-8.2 (-16.9, 0.5) <sup>ab</sup>	103.2±100.9	101.2±106	-6.8 (-15.5, 1.9) <sup>b</sup>	101.5±100.3	108.9±112.1	10.5 (-3.6, 24.5) <sup>a</sup>	0.049
Homocysteine, µmol/L	1	13.2±1.8	12.5±1.7	-5.0 (-10.1, 0.9) <sup>b</sup>	12.7±1.5	13.0±1.8	3.2 (-3.4, 9.8) <sup>a</sup>	13.4±1.8	13.0±1.7	-1.9 (-12.7, 9.0) <sup>ab</sup>	0.29
	2	13.4±2.9	12.8±2.8	-4.8 (-10.0, 0.4)	12.9±2.3	12.9±2.6	0.4 (-8.9, 9.7)	14.3±2.7	13.2±2.6*	-6.9 (-13.9, 0.1)	0.34

Values are means ± SDs; <sup>1</sup>LDL-cholesterol <3.36 mmol/L, 2, LDL-cholesterol ≥3.36 mmol/L; <sup>2</sup>CRP, C-reactive protein. RF, reduced fat product; n-3RF, n-3 enriched reduced fat product; NF, normal fat product; \*p<0.050, \*\*p<0.010, \*\*\*p<0.001 with respect to its respective baseline; Rate of change (%). 100\*(mean (CI 95%) of RF or n-3 RF or NF - baseline/baseline). p+, probability obtained by the general linear model (GLM) of repeated measures. Different letters in the same row (a > b > c, repeated measures followed *post-hoc* LSD, at least p<0.05) indicate significant differences.

Tabla corregida:

**Table 2.** Rate of change of cardiovascular disease markers to the three experimental pork products in subjects with initial low-normal/high LDL-cholesterol values

	Initial LDL-c <sup>1</sup>	Basal RF	Final RF	RF Rate of change	Basal n-3RF	Final n-3RF	n3RF Rate of change	Basal NF	Final NF	NF Rate of change	p+
Total cholesterol, mmol/L	1	5.76±0.73	5.69±0.67	-0.9 (-9.0, 7.2)	5.74±0.79	5.70±0.63	0.1 (-9.9, 10.0)	5.49±0.92	5.92±0.85*	8.5 (0.4, 16.7)	0.22
	2	6.05±0.28	6.13±0.27	1.3 (-1.9, 4.6)	5.84±0.46	6.23±0.58	7.1 (-0.6, 14.8)	6.21±0.74	6.01±0.51	-2.6 (-9.3, 4.0)	0.13
LDL-cholesterol, mmol/L	1	2.89±0.34	3.04±0.66	4.6 (-8.5, 17.7)	3.14±0.52	2.93±0.41	-4.2 (-20.2, 11.8)	2.94±0.41	3.3±0.82*	11.7 (-6.1, 29.6)	0.31
	2	3.75±0.38	3.84±0.54	2.4 (-6.5, 11.3)	3.83±0.67	3.52±0.56*	-7.4 (-12.8, -2.1)	3.86±0.52	4.06±0.79	8.6 (-5.9, 23.1)	0.18
HDL-cholesterol, mmol/L	1	1.14±0.24	1.21±0.26	6.6 (-0.9, 14.1)	1.27±0.22	1.27±0.25	-0.3 (-10.1, 9.5)	1.22±0.2	1.20±0.26	-2.1 (-11.5, 7.4)	0.18
	2	1.21±8.1	1.22±9.2	0.8 (-6.5, 8.1)	1.18±9.0	1.21±8.0	4.0 (-7.2, 15.1)	1.21±7.7	1.27±10.9	4.7 (-6.4, 15.7)	0.80
Triglycerides, mmol/L	1	1.59±1.1	1.37±0.35	10.2 (-24.8, 45.2)	1.22±0.52	1.46±0.59	-24.7 (-12.4, 61.7)	1.53±1.08	1.37±0.64	17.5 (-21.2, 56.3)	0.80
	2	1.39±0.67	1.26±0.62	-3.1 (-30.7, 24.5)	1.40±0.57	1.57±1.06	7.5 (-16.0, 31.0)	1.55±0.83	1.28±0.48	-3.1 (-31.0, 24.7)	0.66
Arylesterase, U/L	1	321±122	385±106	33.4 (-11.0, 77.7)	335±124	438±127**	37.6 (11.4, 63.7)	214±55.2	225±69.4	10.1 (-23.9, 44.2)	0.48
	2	266±62.2	348±108**	29.9 (14.6, 45.2) <sup>b</sup>	240±109	397±119***	81.8 (46.8, 116.8) <sup>a</sup>	196±38.2	179±59.0	-7.7 (-31.1, 15.6) <sup>c</sup>	0.001
oxLDL, U/L	1	53.7±12.2	49.6±7.9	-5.4 (-18.4, 7.6)	53.7±12.2	54.2±15.9	3.7 (-29.7, 37.1)	53.7±12.2	64.9±20.4	22.0 (-5.1, 49.1)	0.17
	2	59.7±7.2	61.9±7.3	4.0 (-3.0, 11.1) <sup>ab</sup>	59.7±7.2	59.8±11.3	0.3 (-9.9, 10.5) <sup>b</sup>	59.7±7.2	65.8±9.1	11.3 (-1.8, 24.5) <sup>a</sup>	0.049
CRP <sup>2</sup> , µg/mL	1	4.0±5.9	3.0±3.2	43.7 (-46.1, 133.5) <sup>a</sup>	3.9±3.4	2.1±2.5**	-61.0 (-92.6, -29.3) <sup>b</sup>	5.4±5.1	5.2±6.8	30.9 (-103, 164) <sup>ab</sup>	0.14
	2	1.8±2.2	1.5±1.0	92.4 (-68.8, 253.7)	1.8±1.4	2.4±3.1	183.8 (-131.5, 499)	1.7±0.8	2.4±2.1	39.8 (-14.4, 94.0)	0.46
TNFα, pg/mL	1	26.4±10.4	17.9±6.9*	-27.1 (-49.9, -4.3)	20.8±9.0	16.8±11.6	-21.2 (-50.5, 8.0)	26.4±17.1	15.3±13.2	-17.8 (76.6, 40.9)	0.87
	2	29.6±15.4	18.7±10.7	-24.5 (-55.1, 6.2)	16.1±12.2	17.9±5.2	140 (-93.3, 373)	21.6±12.7	24.4±15.5	39.2 (-45.0, 123.4)	0.19
apo A1, g/L	1	1.45±0.23	1.47±0.26	1.3 (-2.1, 4.6)	1.47±0.23	1.53±0.28	4.7 (-7.3, 16.6)	1.47±0.24	1.43±0.28	-2.9 (-8.0, 2.2)	0.33
	2	1.39±0.17	1.37±0.18	-1.3 (-5.6, 3.0)	1.36±0.2	1.35±0.17	-0.2 (-7.1, 6.7)	1.37±0.18	1.41±0.24	3.4 (-5.8, 12.7)	0.58
apo B, g/L	1	1.08±0.26	1.04±0.22	-2.8 (-10.3, 4.6)	1.05±0.24	1.00±0.23	-4.4 (-17.7, 8.9)	1.03±0.37	1.04±0.26	3.4 (-7.6, 14.4)	0.51
	2	1.15±0.12	1.15±0.12	0.2 (-4.2, 4.5)	1.10±0.14	1.17±0.14**	6.1 (1.3, 10.6)	1.15±0.11	1.13±0.13	-1.6 (-7.3, 4.2)	0.12
Lp(a), mg/L	1	78.5±95.9	84.7±102.8	7.9 (-15.4, 31.2)	78.1±92.5	74.3±93.5	-6.2 (-21.6, 9.2)	81.4±109.5	85.9±109.4	7.2 (-3.4, 17.8)	0.32
	2	112.1±111.5	98.1±92.4	-8.2 (-16.9, 0.5) <sup>ab</sup>	103.2±100.9	101.2±106	-6.8 (-15.5, 1.9) <sup>b</sup>	101.5±100.3	108.9±112.1	10.5 (-3.6, 24.5) <sup>a</sup>	0.049
Homocysteine, µmol/L	1	13.2±1.8	12.5±1.7	-5.0 (-10.1, 0.9) <sup>b</sup>	12.7±1.5	13.0±1.8	3.2 (-3.4, 9.8) <sup>a</sup>	13.4±1.8	13.0±1.7	-1.9 (-12.7, 9.0) <sup>ab</sup>	0.29
	2	13.4±2.9	12.8±2.8	-4.8 (-10.0, 0.4)	12.9±2.3	12.9±2.6	0.4 (-8.9, 9.7)	14.3±2.7	13.2±2.6*	-6.9 (-13.9, 0.1)	0.34

Values are means ± SDs; <sup>1</sup>LDL-cholesterol <3.36 mmol/L, 2, LDL-cholesterol ≥3.36 mmol/L; <sup>2</sup>CRP, C-reactive protein. RF, reduced fat product; n-3RF, n-3 enriched reduced fat product; NF, normal fat product; \*p<0.050, \*\*p<0.010, \*\*\*p<0.001 with respect to its respective baseline; Rate of change (%). 100\*(mean (CI 95%) of RF or n-3 RF or NF - baseline/baseline). p+, probability obtained by the general linear model (GLM) of repeated measures. Different letters in the same row (a > b > c, repeated measures followed *post-hoc* LSD, at least p<0.05) indicate significant differences.

Recomendamos que consulten el artículo en la versión electrónica de JONNPR (<http://revistas.proeditio.com/jonnpr/article/view/1088/pdf1088>) donde se han incluido las correcciones.